Our Head of Professional and Enterprise Disputes Melanie Ho and Partner Chang Man Phing, and Specialist & Private Client Disputes Partner Alvin Lim recently contributed to the Singapore Chapter in the 11th Edition of The Life Sciences Law Review where they expound on the various regulatory frameworks that govern Singapore’s life sciences industry including the sale and production of health products, clinical trials and competition issues that arise from the pharmaceutical and medical sector. They also share their insights on recent developments in Singapore’s healthcare sector that were driven by the pandemic such as the digitisation of healthcare, amongst others.
The Life Sciences Law Review is an overview of the legal and regulatory frameworks governing pharmaceutical, biotechnology and medical device companies in key jurisdictions worldwide. It covers the major rules and restrictions throughout the life cycle of regulated products, from discovery to clinical trials, the marketing authorisation process and post-approval controls. It also examines the most consequential recent trends and developments in the sector.
Click on the link below to read the full Singapore chapter.